Promising lung cancer combo aims to extend life in Late-Stage trial

NCT ID NCT06211036

Disease control Sponsor: Amgen Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 3 trial tests whether adding tarlatamab to durvalumab helps people with extensive-stage small-cell lung cancer live longer than durvalumab alone. About 563 participants who have already completed initial chemotherapy plus durvalumab will be randomly assigned to one of the two treatments. The main goal is to compare overall survival between the groups.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance: tarlatamab and durvalumab
What this could lead to: If successful, this combination could offer a new, more effective treatment option for people with advanced small-cell lung cancer, potentially extending survival.
What could go wrong: This is a large phase 3 trial, but the combination may not prove better than durvalumab alone. Side effects from adding tarlatamab could be significant, and results may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

563 people

The number who actually took part.

Started

Jun 2024

Expected to finish

Sep 2028

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 99 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion: * Participant has provided informed consent prior to initiation of any study specific activities/procedures. * Age \>= 18 years (or \>= legal adult age within the country if it is older than 18 years). * Completed 3-4 cycles of platinum-etoposide chemotherapy with concurrent durvalumab as first-line treatment of extensive-stage (ES)-SCLC prior to enrollment, without disease progression (ongoing response or stable disease) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1). * Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 to 1. * Minimum life expectancy \> 12 weeks. * Toxicities attributed to prior anti-cancer therapy resolved to grade ≤ 1, unless otherwise specified, excluding alopecia or fatigue. * Adequate organ function. * Histologically or cytologically documented extensive-stage disease (American Joint Committee on Cancer, 2017, IV small-cell lung cancer (SCLC) \[T any, N any, M1 a/b/c\]), or T3 to T4 due to multiple lung nodules that are too extensive or have tumor/nodal volume that is too large to be encompassed in a tolerable radiation plan. Participants with prior limited-stage (LS)-SCLC are allowed if the interval is \> 6 months since the end of previous therapy and progression, in discussion with the medical monitor. Exclusion * Symptomatic central nervous system (CNS) metastases, or leptomeningeal disease. Participants with treated brain metastases are eligible as per protocol. * Prior history of severe or life-threatening events from any immune-mediated therapy. * History of other malignancy within the past 2 years, with some exceptions as per protocol. * Active or prior documented autoimmune or inflammatory disorders as per protocol. * Myocardial infarction and/or symptomatic congestive heart failure (New York Heart Association \> class II) within 6 months of first dose of study treatment. * History of arterial thrombosis (e.g., stroke or transient ischemic attack) within 6 months of first dose of study treatment. * Evidence of interstitial lung disease (ILD) or active, non-infectious pneumonitis. * History of solid organ transplant. * Major surgical procedures within 28 days of first dose of study treatment. * Known human immunodeficiency virus (HIV) infection (participants with HIV infection on antiviral therapy and undetectable viral load are permitted with a requirement for regular monitoring for reactivation for the duration of treatment on study), hepatitis C infection (participants with hepatitis C that achieve a sustained virologic response after antiviral therapy are allowed), or hepatitis B infection (participants with hepatitis B surface antigen \[HBsAg\] or core antibody that achieve sustained virologic response with antiviral therapy are permitted with a requirement for regular monitoring for reactivation for the duration of treatment on the study). * Receiving systemic corticosteroid therapy or any other form of immunosuppressive therapy within 14 days prior to first dose of study treatment. * History of allergic reactions or acute hypersensitivity reaction to antibody therapies, platinum chemotherapy, or etoposide. * Participant with symptoms and/or clinical signs and/or radiographic signs that indicate an acute and/or uncontrolled active systemic infection within 7 days prior to the first dose of study treatment. * Participant has known active infection requiring parenteral antibiotic treatment. Upon completion of parenteral antibiotics and resolution of symptoms, the participant may be considered eligible for the study from an infection standpoint. * Treatment with live virus, including live-attenuated vaccination, within 4 weeks prior to the first dose of study treatment. Inactive vaccines (e.g., non-live or non-replicating agent) and live viral non-replicating vaccines (e.g., Jynneos for Monkeypox infection) within 30 days prior to first dose of study treatment. * Prior therapy with any selective inhibitor of the delta-like ligand 3 (DLL3) pathway. * Receiving another anti-cancer therapy. Adjuvant hormonal therapy for resected breast cancer is permitted. * Treatment in an alternative investigational trial within 28 days prior to enrollment. * Has received or is planning to receive consolidative chest radiation for extensive stage disease. * Female participants of childbearing potential unwilling to use protocol specified method of contraception during treatment as per protocol. * Female participants who are breastfeeding or who plan to breastfeed while on study as per protocol. * Female participants planning to become pregnant or donate eggs while on study as per protocol. * Female participants of childbearing potential with a positive pregnancy test assessed at screening by a highly sensitive serum pregnancy test. * Male participants with a female partner of childbearing potential who are unwilling to practice sexual abstinence (refrain from heterosexual intercourse) or use contraception during treatment as per protocol. * Male participants with a pregnant partner who are unwilling to practice abstinence or use a condom during treatment as per protocol. * Male participants unwilling to abstain from donating sperm during treatment as per protocol. * Participant has known sensitivity to any of the products or components to be administered during dosing. * Participant has known sensitivity to any of the products or components to be administered during dosing. * History or evidence of any other clinically significant disorder, condition or disease that, in the opinion of the investigator or physician if consulted, would pose a risk to participant safety or interfere with the study evaluation, procedures, or completion. * Participant likely to not be available to complete all protocol-required study visits or procedures, and/or to comply with all required study procedures (eg, Clinical Outcome Assessments) to the best of the participant and investigator's knowledge. Participants who are unable to complete clinical outcome assessments are eligible.

Get updates

Get notified about this study

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Extensive-stage small-cell lung cancer Small cell lung cancer

Contacts and locations

Locations

Affiliated Cancer Hospital of Xinjiang Medical University

Ürümqi, Xinjiang, 830054, China
Affiliated Hospital of Guilin Medical University

Guilin, Guangxi, 541001, China
Aichi Cancer Center

Nagoya, Aichi-ken, 464-8681, Japan
Algemeen Ziekenhuis Maria Middelares

Ghent, 9000, Belgium
Allegheny Health Network

Pittsburgh, Pennsylvania, 15212, United States
Allina Health System dba Allina Health Cancer Institute

Saint Paul, Minnesota, 55102, United States
Ankara Bilkent Sehir Hastanesi

Ankara, 06800, Turkey (Türkiye)
Asan Medical Center

Seoul, 05505, South Korea
Asklepios Fachkliniken Muenchen Gauting

Gauting, 82130, Germany
Astera Cancer Care

East Brunswick, New Jersey, 08816, United States
Attikon University Hospital

Athens, 12462, Greece
Azienda Socio Sanitaria Territoriale Grande Ospedale Metropolitano Niguarda

Milan, 20162, Italy
Azorg Campus Aalst - Moorselbaan

Aalst, 9300, Belgium
Bagcilar Medipol Mega Universite Hastanesi

Istanbul, 34214, Turkey (Türkiye)
Baptist Cancer Center Memphis Thoracic

Memphis, Tennessee, 38120, United States
Beaumont Hospital

Dublin, 9, Ireland
Beijing Cancer Hospital

Beijing, Beijing Municipality, 100142, China
Beijing Cancer Hospital

Beijing, 100142, China
Beijing Chaoyang Hospital, Capital Medical University

Beijing, Beijing Municipality, 100020, China
CHU de Quebec Hopital de l Enfant Jesus

Québec, Quebec, G1R 2J6, Canada
Cancer Research South Australia

Adelaide, South Australia, 5000, Australia
Cancer and Hematology Centers of Western Michigan

Grand Rapids, Michigan, 49503, United States
Cangzhou Peoples Hospital

Cangzhou, Hebei, 061011, China
Cenantron Centro Avançado de Tratamento Oncologico Ltda

Belo Horizonte, Minas Gerais, 30130-090, Brazil
Centre Hospitalier - Le Mans

Le Mans, 72000, France
Centre Hospitalier Intercommunal de Creteil

Créteil, 94010, France
Centre Hospitalier Regional Universitaire de Brest - Hopital Morvan

Brest, 29200, France
Centre Hospitalier Universitaire Nord

Marseille, 13915, France
Centre Hospitalier Universitaire de Nantes - Hopital Nord Laennec

Saint-Herblain, 44800, France
Centre Hospitalier Universitaire de Strasbourg - Nouvel Hopital Civil

Strasbourg, 67091, France
Centre Hospitalier Universitaire de Toulouse - Hopital Larrey

Toulouse, 31059, France
Centre Hospitalier Universitaire-Universite Catholique de Louvain Namur-Site Godinne

Yvoir, 5530, Belgium
Centre Leon Berard

Lyon, 69008, France
Centres Hospitaliers Universitaires - Helora - Hopital de Mons - Site Kennedy

Mons, 7000, Belgium
Centro Ricerche Cliniche Di Verona Societa responsabilita limitata

Verona, 37126, Italy
Chris OBrien Lifehouse

Camperdown, New South Wales, 2050, Australia
Chungbuk National University Hospital

Cheongju Chungbuk, 28644, South Korea
Clinica Universidad de Navarra

Pamplona, Navarre, 31008, Spain
Clinique Teissier

Valenciennes, 59300, France
Dana-Farber Cancer Institute

Boston, Massachusetts, 02215, United States
Dolnoslaskie Centrum Onkologii, Pulmonologii i Hematologii

Wroclaw, 53-439, Poland
Duke University

Durham, North Carolina, 27710, United States
Emory University

Atlanta, Georgia, 30322, United States
Erasmus Medisch Centrum

Rotterdam, 3015 GD, Netherlands
European Interbalkan Medical Center

Thessaloniki, 57001, Greece
Exelsus Oncologia Clinica

San Miguel de Tucumán, Tucumán Province, 4000, Argentina
Fakultni nemocnice Brno

Brno, 625 00, Czechia
Fakultni nemocnice Olomouc

Olomouc, 779 00, Czechia
Fakultni nemocnice v Motole

Prague, 150 06, Czechia
Fejer Varmegyei Szent Gyorgy Egyetemi Oktato Korhaz

Székesfehérvár, 8000, Hungary
Franciscan Health Indianapolis

Indianapolis, Indiana, 46237, United States
Fujian Cancer Hospital

Fuzhou, Fujian, 350014, China
Fundacao Antonio Prudente AC Camargo Cancer Center

São Paulo, São Paulo, 01509-900, Brazil
Fundacion Centro Oncológico Riojano Integral para la Investigación y Prevención del Cáncer

La Rioja, F5300COE, Argentina
Fundacion Medica de Rio Negro y Neuquen

Cipolletti, Río Negro Province, 8324, Argentina
Greenslopes Private Hospital

Greenslopes, Queensland, 4120, Australia
Guangxi Medical University Affiliated Tumor Hospital

Nanning, Guangxi, 530201, China
Gyor-Moson-Sopron Varmegyei Petz Aladar Egyetemi Oktatokorhaz

Győr, 9024, Hungary
Health Pharma Professional Research SA de CV

Mexico City, Mexico City, 03100, Mexico
Henan Cancer Hospital

Zhengzhou, Henan, 450003, China
Henry Dunant Hospital Center

Athens, 11526, Greece
Hopital Cochin

Paris, 75014, France
Hospital Britanico de Buenos Aires

CABA, Buenos Aires, C1280AEB, Argentina
Hospital Clinic i Provincial de Barcelona

Barcelona, Catalonia, 08036, Spain
Hospital Cuf Descobertas

Lisbon, 1998-018, Portugal
Hospital Cuf porto

Porto, 4100-180, Portugal
Hospital Israelita Albert Einstein

São Paulo, São Paulo, 05652-900, Brazil
Hospital Regional Universitario de Malaga

Málaga, Andalusia, 29011, Spain
Hospital Sao Rafael-Idor

Salvador, Estado de Bahia, 40170-110, Brazil
Hospital Universitari Vall d Hebron

Barcelona, Catalonia, 08035, Spain
Hospital Universitari i Politecnic La Fe

Valencia, Valencia, 46026, Spain
Hospital Universitario Ramon y Cajal

Madrid, 28034, Spain
Hospital Universitario Virgen Macarena

Seville, Andalusia, 41009, Spain
Hospital Uopeccan

Cascavel, Paraná, 85806-300, Brazil
Hospital da Luz, SA

Lisbon, 1500-650, Portugal
Hospital de Clinicas de Ijui

Ijuí, Rio Grande do Sul, 98700-000, Brazil
Hospital de Clinicas de Passo Fundo

Passo Fundo, Rio Grande do Sul, 99010-260, Brazil
Hospital de la Santa Creu i Sant Pau

Barcelona, Catalonia, 08041, Spain
Hubei Cancer Hospital

Wuhan, Hubei, 430070, China
Hyogo Cancer Center

Akashi-shi, Hyōgo, 673-8558, Japan
IRCCS Istituto Oncologico Europeo

Milan, 20141, Italy
IRCCS Istituto Tumori Giovanni Paolo II

Bari, 70124, Italy
Infirmary Cancer Center

Mobile, Alabama, 36607, United States
Inselspital Bern

Bern, 3010, Switzerland
Institut Bergonie

Bordeaux, 33000, France
Institut Catala d Oncologia Hospitalet Hospital Duran i Reynals

L'Hospitalet de Llobregat, Catalonia, 08908, Spain
Institut Jules Bordet

Brussels, B-1070, Belgium
Institut regional du Cancer Montpellier

Montpellier, 34298, France
Instituto Alexander Fleming

Capital Federal, Buenos Aires, C1426ANZ, Argentina
Institutul Oncologic Prof Dr Ion Chiricuta Cluj-Napoca

Cluj-Napoca, 400015, Romania
Instytut Gruzlicy i Chorob Pluc

Warsaw, 01-138, Poland
Irmandade da Santa Casa de Misericordia de Porto Alegre

Porto Alegre, Rio Grande do Sul, 90020-090, Brazil
Izmir Katip Celebi Universitesi Ataturk Egitim ve Arastirma Hastanesi

Izmir, 35150, Turkey (Türkiye)
Jiamusi Cancer Hospital

Jiamusi, Heilongjiang, 154007, China
Jiangxi Cancer hospital

Nanchang, Jiangxi, 330029, China
Jilin Cancer Hospital

Changchun, Jilin, 130012, China
Juntendo University Hospital

Bunkyo-ku, Tokyo, 113-8431, Japan
Kanagawa Prefectural Hospital Organization Kanagawa Cancer Center

Yokohama, Kanagawa, 241-8515, Japan
Kansai Medical University Hospital

Hirakata-shi, Osaka, 573-1191, Japan
Kantonsspital Sankt Gallen

Sankt Gallen, 9007, Switzerland
Kaohsiung Chang Gung Memorial Hospital

Kaohsiung City, 83301, Taiwan
Kindai University Hospital

Osakasayama-shi, Osaka, 589-8511, Japan
Kliniken der Stadt Koeln gGmbH

Cologne, 51109, Germany
Kurume University Hospital

Kurume-shi, Fukuoka, 830-0011, Japan
Kyushu University Hospital

Fukuoka, Fukuoka, 812-8582, Japan
Landeskrankenhaus Feldkirch

Rankweil, 6830, Austria
Linyi Cancer Hospital

Linyi, Shandong, 276000, China
London Health Sciences Centre

London, Ontario, N6A 5W9, Canada
LungenClinic Grosshansdorf GmbH

Großhansdorf, 22927, Germany
Maastricht Universitair Medisch Centrum

Maastricht, 6229 HX, Netherlands
Matrai Gyogyintezet

Gyöngyös, 3200, Hungary
Mayo Clinic

Rochester, Minnesota, 55905, United States
Medical Park Seyhan Hastanesi

Mersin, 33200, Turkey (Türkiye)
Medical University of South Carolina

Charleston, South Carolina, 29425, United States
Medizinische Universitaet Graz

Graz, 8036, Austria
Meir Medical Center

Kfar Saba, 4428164, Israel
Metropolitan General

Athens, 15562, Greece
Metropolitan Hospital

Athens, 18547, Greece
Monash Medical Centre

Clayton, Victoria, 3168, Australia
Montefiore Medical Center - Bronx

The Bronx, New York, 10461, United States
Nanjing Chest Hospital

Nanjing, Jiangsu, 210029, China
National Cancer Center

Goyang-si Gyeonggi-do, 10408, South Korea
National Cancer Center Hospital

Chuo-ku, Tokyo, 104-0045, Japan
National Cancer Center Hospital East

Kashiwa-shi, Chiba, 277-8577, Japan
National Cheng Kung University Hospital

Tainan, 70403, Taiwan
National Hospital Organization Hokkaido Cancer Center

Sapporo, Hokkaido, 003-0804, Japan
National Hospital Organization Shikoku Cancer Center

Matsuyama, Ehime, 791-0280, Japan
National Taiwan University Hospital

Taipei, 10002, Taiwan
Nebraska Cancer Specialists

Omaha, Nebraska, 68130, United States
Nemocnice Agel Ostrava-Vitkovice as

Ostrava-Vitkovice, 703 00, Czechia
Niigata Cancer Center Hospital

Niigata, Niigata, 951-8566, Japan
Northeast Georgia Medical Center

Gainesville, Georgia, 30501, United States
Odense Universitetshospital

Odense C, 5000, Denmark
Okayama University Hospital

Okayama, Okayama-ken, 700-8558, Japan
Oncare

Mexico City, Mexico City, 03810, Mexico
Oncoclinicas Rio de Janeiro S A

Rio de Janeiro, 22250-905, Brazil
Oncology Associates of Oregon, PC

Eugene, Oregon, 97401, United States
Oncology Hematology Associates

Springfield, Missouri, 65807, United States
Oncology Hematology Care Incorporated

Cincinnati, Ohio, 45242, United States
Oregon Health and Science University

Portland, Oregon, 97239, United States
Orszagos Koranyi Pulmonologiai Intezet

Budapest, 1121, Hungary
Osaka International Cancer Institute

Osaka, Osaka, 541-8567, Japan
Ospedale Regionale di Bellinzona e Vali

Mendrisio, 6850, Switzerland
Our Lady of the Lake Cancer Institute

Baton Rouge, Louisiana, 70808, United States
Prince of Wales Hospital, Chinese University of Hong Kong

Shatin, New Territories, Hong Kong
Princess Margaret Hospital

Kowloon, Hong Kong
Rabin Medical Center

Petah Tikva, 4941492, Israel
Rambam Medical Center

Haifa, 3109601, Israel
Reformatus Pulmonologiai Centrum

Törökbálint, 2045, Hungary
Regionshospitalet Godstrup

Herning, 7400, Denmark
Rigshospitalet

Copenhagen, 2100, Denmark
Rutgers Cancer Institute of New Jersey

New Brunswick, New Jersey, 08901, United States
Saint Lukes Hospital SA

Thessaloniki, 55236, Greece
Saitama Medical University International Medical Center

Hidaka-shi, Saitama, 350-1298, Japan
Sakarya Egitim ve Arastirma Hastanesi

Sakarya, 54290, Turkey (Türkiye)
Samsung Medical Center

Seoul, 06351, South Korea
Santa Casa de Misericordia de Passos

Passos, Minas Gerais, 37904-020, Brazil
Sarah Cannon Research Institute

Nashville, Tennessee, 37203, United States
Semmelweis Egyetem

Budapest, 1083, Hungary
Seoul National University Bundang Hospital

Seongnam-si, Gyeonggi-do, 13620, South Korea
Seoul National University Hospital

Seoul, 03080, South Korea
Severance Hospital Yonsei University Health System

Seoul, 03722, South Korea
Shaare Zedek Medical Center

Jerusalem, 9103102, Israel
Shanghai Chest Hospital

Shanghai, Shanghai Municipality, 200030, China
Shanghai Pulmonary Hospital

Shanghai, Shanghai Municipality, 200433, China
Shanxi Provincial Cancer Hospital

Taiyuan, Shanxi, 030009, China
Shizuoka Cancer Center

Sunto-gun, Shizuoka, 411-8777, Japan
Sir Charles Gairdner Hospital

Nedlands, Western Australia, 6009, Australia
Sotiria General Hospital

Athens, 11527, Greece
Spitalul Municipal Ploiesti

Ploieşti, 100337, Romania
Sun Yat-sen University Cancer Center

Guangzhou, Guangdong, 510060, China
Swedish Cancer Institute

Seattle, Washington, 98104, United States
Taipei Veterans General Hospital

Taipei, 11217, Taiwan
Texas Oncology - Dallas Fort Worth

Dallas, Texas, 75246, United States
The Affiliated Cancer Hospital of Shandong First Medical University

Jinan, Shandong, 250117, China
The Affiliated Hospital of Inner Mongolia Medical University

Hohhot, Inner Mongolia, 010010, China
The Cancer Institute Hospital of Japanese Foundation for Cancer Research

Koto-ku, Tokyo, 135-8550, Japan
The First Affiliated Hospital Of Ningbo University

Ningbo, Zhejiang, 315010, China
The First Affiliated Hospital of Wenzhou Medical University

Wenzhou, Zhejiang, 325015, China
The First Affiliated Hospital of Xian Jiaotong University

Xi’an, Shanxi, 710065, China
The First Affiliated Hospital of Zhengzhou University

Zhengzhou, Henan, 450066, China
The Medical College of Wisconsin

Milwaukee, Wisconsin, 53226, United States
The Ohio State University

Columbus, Ohio, 43210, United States
The Second Attached Hospital Of Fujian Medical University

Quanzhou, Fujian, 362002, China
Tianjin Peoples Hospital

Tianjin, Tianjin Municipality, 300121, China
US Oncology Research Investigational Products Center

Dallas, Texas, 75246, United States
Unidade Local de Saude de Matosinhos, EPE - Hospital Pedro Hispano

Matosinhos Municipality, 4464-513, Portugal
Universitaetsklinikum Dresden

Dresden, 01307, Germany
Universitaetsklinikum Essen

Essen, 45147, Germany
Universitaetsklinikum Heidelberg

Heidelberg, 69126, Germany
Universitaetsklinikum Krems

Krems, 3500, Austria
Universitaetsklinikum Wuerzburg

Würzburg, 97078, Germany
Universitaetsspital Basel

Basel, 4052, Switzerland
Universitair Medisch Centrum Groningen

Groningen, 9713 GZ, Netherlands
Universitair Ziekenhuis Antwerpen

Edegem, 2650, Belgium
Universitair Ziekenhuis Brussel

Brussels, 1090, Belgium
Universite Catholique de Louvain Cliniques Universitaires Saint Luc

Brussels, 1200, Belgium
University Cancer and Blood Center LLC

Athens, Georgia, 30607, United States
University Hospital Muenster

Münster, 48149, Germany
University Hospitals Cleveland Medical Center

Cleveland, Ohio, 44106, United States
University of Illinois Chicago

Chicago, Illinois, 60612, United States
University of Pittsburgh Medical Center

Pittsburgh, Pennsylvania, 15232, United States
University of Southern California

Los Angeles, California, 90033, United States
University of Texas MD Anderson Cancer Center

Houston, Texas, 77030, United States
Uniwersyteckie Centrum Kliniczne

Gdansk, 80-214, Poland
VM Medical Park Mersin Hastanesi

Mersin, 33200, Turkey (Türkiye)
Virginia Commonwealth University Massey Cancer Center

Richmond, Virginia, 23298, United States
Virginia Oncology Associates

Newport News, Virginia, 23606, United States
Vseobecna fakultni nemocnice v Praze

Prague, 128 08, Czechia
Wakayama Medical University Hospital

Wakayama, Wakayama, 641-8510, Japan
Wake Forest University Health Sciences

Winston-Salem, North Carolina, 27157, United States
West China Hospital of Sichuan University

Chengdu, Sichuan, 611135, China
Wielkopolskie Centrum Pulmonologii i Torakochirurgii imienia Eugenii i Janusza Zeylandow

Poznan, 60-569, Poland
Wollongong Hospital

Wollongong, New South Wales, 2500, Australia
Xinqiao Hospital

Chongqing, Chongqing Municipality, 400037, China
Xuzhou Central Hospital

Xuzhou, Jiangsu, 221009, China
Yale New Haven Hospital

New Haven, Connecticut, 06510, United States
Ziekenhuis Oost-Limburg

Genk, 3600, Belgium
the First Affiliated Hospital Zhejiang University School of Medicine

Hangzhou, Zhejiang, 310003, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.